LUND, SWEDEN – Immunovia AB (Nasdaq Stockholm: IMMNOV) today announced that itenters into a strategic partnership with Proteomedix to leverage its substantial jointdevelopment experience in diagnostic technologies for the detection of cancer. This willenable increased R&D productivity for Immunovia as the Company continues to strengthenits commercial development in the US.
The partnership between Immunovia and Proteomedix leverages the companies’complementary R&D capabilities and advances their R&D efforts. With this partnership,Immunovia will gain a more flexible R&D organization, increase its R&D productivity, and willfocus internal resources on the commercial build up, thus further accelerating the roll-out ofIMMray™ PanCan-d. The partnership capitalizes on the combined expertise of two leadinginnovators in proteomics-based diagnostics, who have both launched innovative oncologytests, Immunovia with IMMray™ PanCan-d in the U.S. and Proteomedix with Proclarix® inEurope.
Proteomedix, a Swiss based Company, was founded 2010 as a spin-off company of ETHZurich to bring together the expertise of a multi-disciplinary group of world-leading scientistsand clinicians in proteomic-based diagnostics. The Company is focused on research anddevelopment that relies on a network of clinicians, IVD experts, laboratories, and marketers.Proteomedix has developed a blood-based prostate cancer test using proteomics technologythat measures cancer-associated proteins, using highly reproducible immunoassays.“We are very excited to enter this partnership with Immunovia, an early-commercialcompany like us with an innovative diagnostic test in oncology. This partnership enablesboth companies to faster take critical steps forward by leveraging our combined expertise toincrease R&D efficiency. For Proteomedix, this partnership demonstrates how our biomarkerassay development expertise can be deployed beyond prostate cancer.”, said HelgeLubenow – CEO, Proteomedix.
“Immunovia is entering a new phase with an increased focus on the commercialization ofour IMMray™ PanCan-d test in the US while maximizing our R&D productivity. Thispartnership with Proteomedix will combine leading proteomics-based researchers withstate-of-the art capabilities from both companies to create an outstanding R&D platform,”said Philipp Mathieu – CEO and President, Immunovia.In connection with the new R&D partnership, Linda Dexlin Mellby, Vice President Research &Development at Immunovia, will be leaving the company as of 4 November.
“Linda has been instrumental in the development of Immunovia’s IMMray™ PanCan-d testover the past nine years. We thank her for her many contributions to the company and wishher all the best in her future endeavors,” continued Philipp Mathieu – CEO and President,Immunovia.
For more information, please contact:Philipp MathieuCEO and Presidentphilipp.email@example.com
Karin Almqvist LiwendahlChief Financial Officerkarin.firstname.lastname@example.orgThe information in this report is information that Immunovia AB is obliged to make publicpursuant to the EU Market Abuse Regulation. The information was submitted for publication,through the agency of the contact person set out above, at 08:30 am CET on October 17,2022.
About ImmunoviaImmunovia AB is a diagnostic company with the vision to revolutionize blood-baseddiagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available for earlydetection of pancreatic cancer. The test has unmatched clinical performance.Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc.For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patientadvocacy groups globally to make this test available to all high-risk pancreatic cancergroups.
The USA, the first market in which IMMray™ PanCan-d is commercially available, is theworld’s largest market for the detection of pancreatic cancer with an estimated value ofmore than USD 4 billion annually.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information,please visit https://immunovia.com/
About ProteomedixProteomedix is a healthcare company whose mission is to transform prostate cancerdiagnosis. The company has identified novel biomarker signatures with utility in prostatecancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood
based prostate cancer test panel and risk score currently available in Europe. Proteomedix islocated in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information,visit www.proteomedix.com.